OnePin Peptide Library · Hormonal
Letrozole (Femara)
Femara
Letrozole, marketed primarily as Femara, is an orally active non-steroidal aromatase inhibitor (AI) developed by Novartis and approved by the FDA in 1997 for the treatment of hormone-receptor-positive breast cancer in postmenopausal women. It is a triazole-class competitive, reversible inhibitor that binds the heme iron of the aromatase enzyme (CYP19A1) and prevents the conversion of androgens into estrogens. Among clinically used aromatase inhibitors it is the most potent, producing > 99% whole-body aromatase suppression and plasma estradiol reductions approaching the assay limit of detection.
For off-label estrogen control, start at a very low dose - 0.25mg EOD or even 2x per week. Letrozole is the most potent AI available and crashing estradiol happens fast. Confirm a pre-cycle sensitive estradiol baseline and recheck at 10-14 days. Symptoms of over-suppression (joint pain, flat libido, depressive mood, dry skin, lipid damage) should drive a dose reduction or discontinuation immediately. For the FDA-approved breast cancer indication, 2.5mg daily is the standard dose.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Aromatase (CYP19A1) converts androgens - testosterone and androstenedione - into estrogens - estradiol and estrone. Letrozole is a triazole that competitively occupies the aromatase active site and coordinates to the heme iron, blocking substrate access. The binding is reversible, so enzyme activity returns as drug clears; this differs from the irreversible binding of exemestane.
Aromatase (CYP19A1) converts androgens - testosterone and androstenedione - into estrogens - estradiol and estrone. Letrozole is a triazole that competitively occupies the aromatase active site and coordinates to the heme iron, blocking substrate access. The binding is reversible, so enzyme activity returns as drug clears; this differs from the irreversible binding of exemestane.
Its high potency means very low doses produce near-complete suppression - clinical dosing of 2.5mg daily reduces plasma estradiol by more than 99% in postmenopausal women, and even 0.5mg produces near-maximal suppression in most individuals. For men on aromatizable cycles, this means the typical off-label dose is a small fraction of the cancer-treatment dose. Reversible binding also means estrogen rebounds quickly between doses if intervals are too long, so steady scheduling matters more than with exemestane.
Because Letrozole has no intrinsic androgenic activity (it is a synthetic triazole, not an androgen analog), it tends to produce a stronger lipid shift (HDL drop, LDL rise) than exemestane at equivalent estrogen suppression. Long-term use is also associated with measurable bone mineral density loss, a direct consequence of profound estrogen deprivation.
What to expect
First 3-7 days: near-maximal aromatase suppression achieved. Estrogen-related water weight and blood pressure begin to drop. Joint pain may emerge within this window if the dose is too aggressive.
Weeks 2-4: estrogen stabilizes at the dose-dependent set point. Gynecomastia symptoms resolve in most users if dose is appropriate. This is the window to draw a sensitive E2 and fine-tune the dose - symptom-only dosing is not sufficient given Letrozole's potency.
Beyond 4 weeks on a stable dose: estrogen remains steady. Monitor lipids and bone markers on long runs. Post-cycle recovery of aromatase function is relatively quick (3-6 days to full return) because binding is reversible.
Evidence
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Keep separate
Side effects & safety
Commonly reported
- Joint pain and stiffness (more prominent than with exemestane at equivalent suppression)
- Reduced libido and erectile quality if E2 is over-suppressed
- Depressive mood and fatigue with low E2
- Hot flashes (common in women; occurs in men with crashed E2)
- Lipid shift - HDL drop and LDL rise more pronounced than with steroidal AIs
- Dry skin and dry eyes
Less common & notes
- Insomnia, headache, hair thinning, decreased bone mineral density on long-term use (osteopenia or fracture risk), mild elevation of liver enzymes, nausea.
- Rare but reportable: severe depression with over-suppression, significant osteoporotic fracture on multi-year adjuvant use, hypersensitivity reactions, cardiovascular events during long-term oncology treatment.
- Estrogen crash below ~15 pg/mL for extended periods is the most common cause of symptomatic side effects in men on cycle - recognize early and reduce dose.
Pharmacokinetics
Storage. Store at controlled room temperature (20-25°C / 68-77°F). Protect from moisture and light. Keep in original container. Shelf life typically 3 years from manufacture date for tablets. Research-grade oral suspensions should be refrigerated after opening and used within 30-60 days. Keep out of reach of children.
Regulatory status
Prescription medication (Rx) in the United States. FDA-approved brand: Femara (Novartis). Generic letrozole is widely available and significantly less expensive than branded Femara. Not a controlled substance. Off-label use in men for estrogen control or gynecomastia rescue is common but legally requires a valid prescription. Research liquid forms marketed for research purposes are not FDA-regulated for human use. Internationally classified as a prescription drug in most jurisdictions.
Put it to work
Calculate, log & track
Open Letrozole (Femara) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Letrozole (Femara) in the app →Go deeper
The guide & community
The complete Letrozole (Femara) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗